MGI Pharma Adding Three Compounds in Three Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Mergers with Aesgen and Zycos and a licensing deal with Supergen give MGI pipeline products that dovetail with the sales needs of its existing anti-emetic Aloxi.
You may also be interested in...
MGI Pharma Saforis “Approvable” Letter Seeks More Data
FDA is asking the company to conduct an additional Phase III trial to establish efficacy of oral mucositis therapy.
MGI Pharma Saforis “Approvable” Letter Seeks More Data
FDA is asking the company to conduct an additional Phase III trial to establish efficacy of oral mucositis therapy.
MGI To File Saforis NDA For Oral Mucositis By October
The company plans to file the fast-track NDA based on the results of one Phase III trial. A second trial will be initiated after the filing in order to expand the market potential and support a European filing, MGI says.